Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 2, 2012, Pages 252-259

  Tatara, Ayaka ^a   Shimizu, Saki ^a   Shin, Noriyuki ^a   Sato, Maho ^a   Sugiuchi, Tomone ^a   Imaki, Junta ^a   Ohno, Yukihiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

5 HT receptors; Antidepressants; Antipsychotics; Depression; Extrapyramidal side effects; Mood disorders

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLOMIPRAMINE; FLUOXETINE; HALOPERIDOL; LITHIUM CARBONATE; MIANSERIN; MIRTAZAPINE; MOOD STABILIZER; ONDANSETRON; PAROXETINE; RITANSERIN; SB 258585; SEROTONIN 6 ANTAGONIST; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HYPOKINESIA; MALE; MICE; RATS;

EID: 84862876114     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.04.008     Document Type: Article

References (39)

1. Alex K.D., Pehek E.A. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007, 113:296-320.
2. Anttila S.A., Leininen E.V. A review of the pharmacological and clinical profile of mirtazapine. CNS Drugs 2001, 7:249-264.
3. Bonsi P., Cuomo D., Ding J., Sciamanna G., Ulrich S., Tscherter A., et al. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 2007, 32:1840-1854.
4. Chen J., Gao K., Kemp D.E. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011, 24:10-17.
5. DeBattista C., DeBattista K. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr Opin Psychiatry 2010, 5:263-266.
6. Fernández J., Alonso J.M., Andrés J.I., Cid J.M., Díaz A., Iturrino L., et al. Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem 2005, 48:1709-1712.
7. Gelenberg A.J., Hopkins H.S. Antipsychotics in bipolar disorder. J Clin Psychiatry 1996, 57:49-52.
8. Gill H.S., DeVance C.L., Risch S.C. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997, 17:377-389.
9. Gillman P.K. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol 2006, 21:117-125.
10. Govoni S., Racchi M., Masoero E., Zamboni M., Ferini-Strambi L. Extrapyramidal symptoms and antidepressant drugs: neuropharmacological aspects of a frequent interaction in the elderly. Mol Psychiatry 2001, 6:134-142.
11. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20:389-409.
12. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version 3 - the final common pathway. Schizophr Bull 2009, 35:549-562.
13. Imaki J., Mae Y., Shimizu S., Ohno Y. Therapeutic potential of α2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett 2009, 454:143-147.
14. Ishibashi T., Ikeda K., Ishida K., Yasui J., Tojima R., Nakamura M., et al. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Eur J Pharmacol 1996, 303:247-251.
15. Ishida K., Ohno Y., Ishibashi T., Nakamura M. Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H] acetylcholine release from rat striatal slices. Gen Pharmacol 1996, 27:1203-1207.
16. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
17. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
18. McElroy S.L., Guerdjikova A., Mori N., Keck P.E. Therapeutic potential of new second generation antipsychotics for major depressive disorder. Expert Opin Investig Drugs 2010, 19:1527-1544.
19. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991, 17:263-287.
20. Meltzer H.Y., Stahl S.M. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 1976, 2:19-76.
21. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172.
22. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993, 265:207-217.
23. Nemeroff C.B. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005, 66:13-21.
24. Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther 2011, 17:58-65.
25. Ohno Y., Ishida K., Ikeda K., Ishibashi T., Okada K., Nakamura M. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Pharmacol Biochem Behav 1994, 49:19-23.
26. Ohno Y., Ishida-Tokuda K., Ishibashi T., Sakamoto H., Tagashira R., Horisawa T., et al. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone. Pol J Pharmacol 1997, 49:213-219.
27. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., et al. Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1302-1307.
28. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., et al. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 2008, 55:717-723.
29. Ohno Y., Shimizu S., Imaki J. Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci 2009, 109:593-599.
30. Ohno Y., Imaki J., Mae Y., Takahashi T., Tatara A. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors. Neuropharmacology 2011, 60:201-208.
31. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Elsevier, Manhattan. 6th ed.
32. Prinssen E.P., Colpaert F.C., Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002, 453:217-221.
33. Richelson E. Pharmacology of antidepressants - characteristics of the ideal drug. Mayo Clin Proc 1994, 69:1069-1081.
34. Richelson E., Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984, 103:197-204.
35. Shimizu S., Tatara A., Imaki J., Ohno Y. Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:877-881.
36. Tohen M., Vieta E. Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord 2009, 11:45-54.
37. Wadenberg M.L., Young K.A., Richter J.T., Hicks P.B. Effects of local application of 5-hydroxytryptamine into the dorsal or medial raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology 1999, 38:151-156.
38. Wikström H.V., Mensonides-Harsema M.M., Cremers T.I., Moltzen E.K., Arnt J. Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c, f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem 2002, 45:3280-3285.
39. Wood M.D., Thomas D.R., Watkins C.J., Newberry N.R. Stereoselective interaction of mianserin with 5-HT3 receptors. J Pharm Pharmacol 1993, 45:711-714.